Therapy Type: Immunotherapy (passive) (timeline)
Target Type: Amyloid-Related (timeline)
Condition(s): Alzheimer's Disease
U.S. FDA Status: Alzheimer's Disease (Discontinued)
Company: Eli Lilly & Co.
LY2599666 is an Fc-less, antigen-binding fragment of a monoclonal anti-Aβ antibody linked to polyethylene glycol. It targets soluble Aβ monomer and is delivered by subcutaneous injection.
In December 2015, Eli Lilly started a large Phase 1 trial, comparing LY2599666 to placebo and to solanezumab, the company's anti-Aβ antibody, in 130 volunteers. Solanezumab was administered by intravenous infusion, whereas LY2599666 was injected under the skin. This multicenter study in the United States and Japan compared these two agents on the same safety, pharmacokinetic, and plasma Aβ outcomes. The trial enrolled people who were either cognitively healthy or had a clinical diagnosis of amnestic MCI due to AD or mild to moderate Alzheimer's ascertained by amyloid PET. The trial compared a single injection of LY2599666, a three-month course of weekly injections of up to 200 mgs LY2599666, to a three-month course of either weekly or monthly infusions of solanezumab. In January 2017, Lilly terminated this compound, and at AAIC in July of 2017, reported that it was generally well tolerated but had low target engagement (Hake et al, 2017).
Last Updated: 11 Nov 2016
No Available Further Reading